Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR) is a pharmaceutical company focused on developing and commercializing oral lipid-lowering medicines to treat patients with high cholesterol and related cardiovascular conditions. Founded in 2008, the company specializes in therapies targeting elevated LDL cholesterol through innovative oral agents, aiming to provide additional options for patients who require more effective lipid management.
Company News
Esperion Therapeutics plans to raise approximately $75 million through a public offering of 30 million shares at $2.50 per share, with underwriters having an option to purchase an additional 4.5 million shares.
Esperion Therapeutics plans to conduct an underwritten public offering of common stock, with Piper Sandler and Cantor Fitzgerald as joint book-running managers. The offering is subject to market conditions and will be made through a prospectus supplement.
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mutual funds and institutional investors put cash into the market at the end of this month.
Penny stocks to watch with big news. The post Trading Penny Stocks This Week? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.